Medrad Inc.

Additional Clinical Studies and Technological Advancements for the Cotavance Catheter Underway

Groundbreaking Study Will Evaluate the Combination of Hawk Plaque Excision and the Cotavance Drug-Eluting Angioplasty Balloon for the Treatment of Lower Extremity Peripheral Arterial Disease

MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease

WARRENDALE, Pennsylvania, May 17, 2011 - MEDRAD, INC., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance(TM) Paclitaxel Coated Balloon Angioplasty Catheter with Paccocath(R) technology.

MORE..

WARRENDALE, Pennsylvania, April 8, 2010 - MEDRAD Interventional(TM)/Possis(R) today announced the initiation of a supply agreement with ev3 Inc.

MORE..

Older News

WARRENDALE, Pennsylvania, January 27 - MEDRAD, Inc.

MORE..